Klimek Konrad, Groener Daniel, Chen Xinyu, Rowe Steven P, Speer Thimoteus, Higuchi Takahiro, Werner Rudolf A
Goethe University Frankfurt, University Hospital, Department of Nuclear Medicine, Clinic for Radiology and Nuclear Medicine, Frankfurt, Germany.
Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Bavaria 86156, Germany.
Theranostics. 2024 Oct 21;14(18):7111-7121. doi: 10.7150/thno.102552. eCollection 2024.
Cardiorenal syndrome (CRS) involves bidirectional crosstalk between the failing heart and the kidneys. Depending on the (primary cardiac or renal injury), systems-based interactions in the secondary affected organ may include pro-fibrotic signaling, overzealous inflammation, impaired nerve integrity or overactivity of specific renal transporters mediating glucose absorption. Those pathophysiological pillars can be investigated by molecular imaging using SPECT or PET agents. Targeted whole-body molecular imaging may allow for a) systems-based analysis along the heart-kidney axis, b) may provide prognostic information on longitudinal organ-based functional decline or c) may be used for guidance of reparative intervention based on peak activation identified on PET (paradigm of cardiorenal theranostics). We will discuss the current state of translational molecular imaging for CRS, along with future clinical aspects in the field.
心肾综合征（CRS）涉及衰竭心脏与肾脏之间的双向交互作用。根据（原发性心脏或肾脏损伤）情况，继发性受累器官中基于系统的相互作用可能包括促纤维化信号传导、过度炎症反应、神经完整性受损或介导葡萄糖吸收的特定肾转运蛋白活性过高。这些病理生理支柱可以通过使用单光子发射计算机断层扫描（SPECT）或正电子发射断层扫描（PET）剂的分子成像来研究。靶向全身分子成像可以实现以下几点：a）沿心肾轴进行基于系统的分析；b）可以提供关于纵向器官功能衰退的预后信息；c）可用于基于PET上确定的峰值激活来指导修复性干预（心肾诊疗一体化模式）。我们将讨论CRS转化分子成像的当前状况以及该领域未来的临床方面。
